Summary We have produced adriamycin (ADM)-resistant variants of the human lung cancer cell lines NCI-H69 (small cell), MOR (adenocarcinoma) and COR-L23 (large cell) but have failed to produce resistant variants of two other small cell lines. In each case, the derivation protocol took 7-9 months and included a period of drug-free growth. All three resistant lines show reduced cellular content of ADM after 1 h exposure when compared with their controls. During prolonged incubation of control and resistant NCI-H69 cells in 0.4 jgml -ADM, the ADM content of resistant cells was 6-7 times lower than that of control cells. The ratio of ADM doses to suppress growth of the two lines, however, was in the range 40-200X. The ADMresistant variant of NCI-H69 was also resistant to vincristine, colchicine, VP16, mitozantrone, 4'epiadriamycin and 4'deoxyadriamycin, somewhat resistant to melphalan but not resistant to aclacinomycin A, bleomycin or CCNU. The resistance to ADM could be partially overcome by the use of verapamil, an inhibitor of calcium transport.
There are numerous reports in the literature of the development of cell lines which are resistant to the anthracycline drugs daunorubicin and doxorubicin (adriamycin, ADM). Most of these lines are either leukaemias or ascites tumours of rodent origin (Dano, 1972; Johnson et al., 1976; Nishimura et al., 1978; Belli & Harris, 1979) . Recently, however, ADM-resistant sublines have been obtained from a murine fibrosarcoma (Giavazzi et al., 1983) and from human ovarian cancer lines (Hamilton et al., 1983) . A number of mechanisms of resistance have been identified including defective drug accumulation due to increased active efflux (Dano, 1973) , increased intracellular glutathione (Babson et al., 1981) and decreased amounts of cellular enzymes (Mungikar et al., 1981) . Adriamycin resistance is closely associated with the phenomenon of pleiotropic or multi-drug resistance (Bech-Hansen et al., 1976) where collateral resistance to vincristine and colchicine is observed. This form of resistance is thought to be associated with the presence in the cell membrane of a glycoprotein of 170 K molecular weight (the pglycoprotein) (Ling, 1982) and a gene amplification (Roninson et al., 1984) .
As part of our laboratory studies of drug resistance in human lung cancer, we wished to produce adriamycin-resistant sub-lines of human lung cancer cell lines. In this paper we describe the derivation of such lines and their partial characterisation.
Materials and methods Cell lines and culture conditions
The cell lines used in this study were small cell line NCI-H69 (kindly supplied by Dr D. Carney of the NCI-Navy Medical Oncology Branch) and derived from a patient who had previously received multidrug (including ADM) therapy, small cell lines COR L-32 and COR L-47 derived in this laboratory from previously untreated patients (Baillie-Johnson et al., 1985) , adenocarcinoma line MOR (kindly supplied by Dr M. Ellison, Ludwig Institute, Sutton) and large cell anaplastic line COR-L23 derived in this laboratory (Baillie-Johnson et al., 1985) . All For NCI-H69 and its variants, bulk culture was mechanically disaggregated and an aliquot of this then reduced to a single cell suspension using trypsin/versene. The aliquot was then counted and on the basis of this count, the mechanicallydisaggregated suspension was diluted as appropriate. For MOR and COR-L23 (and their variants) cells for experiments were obtained from a number of growth flasks using trypsin/versene. Dishes were incubated for a period of time equal to that needed for cells in control dishes to be approaching the end of exponential phase growth (6-8 days) as determined from growth curves. Hence within a given experiment, dishes which contained resistant variant cells were counted 1-2 days after dishes containing control cells. Cells from each dish were harvested into a single cell suspension using trypsin/versene and phase-contrast viable cells were counted using a haemocytometer.
ADM-uptake experiments
The method used to determine ADM content per cell was essentially that of Schwartz (1973) . In short-term experiments with NCI-H69 and its resistant variants, incubation was carried out in volumes of 2 ml in polystyrene centrifuge tubes. Each tube contained 2-5 x IO' cells ml-1 of a mechanically-disaggregated suspension from a bulk culture which had been medium changed 48 and 24 h previously. Resistant variants were grown in medium without ADM for 48 h before the experiment. Appropriate concentrations of ADM were added to the tubes and they were incubated at 37°C with agitation every 10 min. After the appropriate time (usually 1 h), the tubes were centrifuged at room temperature for 5 min at 200 g and the medium removed. The cell pellet was rinsed twice in complete medium at room temperature with centrifugation as above. A volume of 0.2 ml of ice-cold sodium lauryl sulphate solution (0.1%) was then added to each tube and the tubes vortexed. A volume of 0.2ml of ice-cold silver nitrate solution (33% w/v) was then added and the tubes were shaken at 4°C for 10 min. At the end of this time, 4 ml of iso-amyl alcohol were added and a further 10 min shaking carried out followed by centrifugation for 5 min at 200g. The alcohol layer from each tube was then transferred to a 5 ml pyrex glass tube and fluorescence was measured in a Perkin-Elmer MPF4 spectrofluorimeter with an excitation wavelength of 490 nm and an emission wavelength of 595 nm. Standards were prepared by adding appropriate amounts of ADM to tubes containing untreated cells following the addition of the silver nitrate solution.
Experiments with MOR and COR-L23 cells were carried out by setting up a series of 25 cm2 flasks at 6 days before the experiments. Numbers of cells per flask were adjusted so that flasks of parent cells and resistant sublines would contain the same numbers of cells at the time of the experiments. ADM exposure and the double rinse were then carried out on growing monolayers of cells and the cells subsequently harvested using trypsin/versene, counted on a haemocytometer and assayed for ADM content as above.
Results

Isolation of resistant sublines
In this section, serial microscopic observations on cells in cultures are reported. For these purposes, cultures are considered to be 'growing well' when their rate of cell multiplication is approximately equal to that seen in control cultures of the same line. 'Slow growth' indicates that cell numbers at least double over a period of one week. 'Viability' of cells is based on their appearance under phase contrast microscopy.
Ist Series In the first series of experiments the results for the individual lines were: NCI-H69
The cells would grow well in 0.01 jig ml-1 of ADM and relatively slowly at 0.02 jg ml -'. Slow growth at 0.05 4ugml -was achieved by 14 weeks and at 0.10pgml-F by 35 weeks. No growth at 0.20 Mg ml'-was achieved up to 1 year.
COR-L32 and COR-L47
Cells of line COR-L32 and COR-L47 would grow well at 0.01 Mg ml-' of ADM. COR-L32 was transferred to 0.02 Mg ml-1 on several occasions over a period of 6 months but never grew at this concentration. and cells were growing well in 0.4Mgml-1 after a total of 13 weeks following re-addition of drug. The sublines growing continuously in 0.10 and 0.40 g ml-' have been designated H69/LX and H69/LX4 respectively and have been used in most experiments described below. Hence the total time to obtain line H69/LX4 was around 7 months. We have subsequently increased further the ADM concentration for growth of this subline and now have a population growing progressively (albeit very slowly) in 4.0 ugmlg-'.
COR-L32 and COR-L47 Despite a series of attempts, using the strategy above, resistant variants of these lines have not emerged.
MOR and COR-L23
Line MOR was grown successively at 0.02, 0.05 and 0.1,ugml-P. At 0.2,ugml-', no growth was observed and the drug was removed after 2 weeks. Small areas of rapid cell growth were seen in the monolayer after 5 weeks and ADM was re-added at 0.2 Mg ml -'. Good growth was observed at this concentration after 6 weeks. The total time to obtain this subline was hence about 7 months. The line has since been adapted to 0.8Mgml-1 over an additional 6 months. The time course of resistance development for COR-L23 was rather similar. Successful growth at 0.2Mgml-' was established again after a total time of about 7 months. We have subsequently been unable to increase any further the ADM concentration for continued growth of this line.
Properties of resistant lines -NCI-H69
In comparing the properties of parent line NCI-H69 with its ADM-resistant variants, the parent cells (designated 'H69/P') were always maintained under similar passage number and conditions as the variants (designated 'H69/LX' and 'H69/LX4').
Growth rate A series of experiments was performed in which 6 cm diameter dishes of H69/P and H69/LX4 cells were set up (2 x 105 cells in 5 ml medium) and cells in representative dishes counted on successive days. The data from these experiments were combined and exponential lines fitted by computer to the points lying between 105 and 2 x 106 cells per flask, i.e. after an initial lag phase and before entry to plateau phase. Stability of resistance We tested the resistance to ADM of subline H69/LX4 after 3 and 9 weeks growth in the absence of drug. At 3 weeks the ID80 (see 'Drug Sensitivity' below) of H69/LX4 (drug free) was 0.20 jigml-P compared with 0.016 gml-1 for parent line H69/P and 0.4ygml-1 for H69/LX4 maintained in ADM. After 9 weeks the ID80 for H69/LX4 (drug free) was 0.20 yg ml-1 compared with 0.018jigml-' for H69/P and 0.4pgml-1 for H69/LX4 maintained in ADM. The resistance factors [i.e. ID80 (resistant line)/ID80 (parent line)] for H69/LX4 out of drug were therefore 12 and 11 after 3 and 9 weeks respectively compared with 25 and 22 for H69/LX4 in drug. Partial loss of resistance therefore occurs within 3 weeks but no further loss is seen between 3 and 9 weeks of drugfree growth.
Drug sensitivity The relative sensitivity to ADM of parent (H69/P) and resistant (H69/LX, H69/LX4) cells is shown in Figure 1 . For each subline, the ID80 was calculated as the drug dose at which the best line fitted by eye to the points crosses the level at which the number of cells per dish is 20% of control. We chose ID80 as (a) the response curves were generally steepest lower down and (b) as untreated cells increase their number by 10-20 x over the period of experiment, the ID80 value Table I. corresponds to at least one doubling by the treated cells. Here in Figure 1 the ID80 values are 0.015, 0.06 and 0.55 Mg ml-1 for H69/P, H69/LX and H69/LX4 respectively. The results of similar experiments carried out for ADM and a variety of other cytotoxic drugs are shown in Tables I and II. It may be seen from Table I that values of ID80 for H69/P cells to ADM cover a range of 7 x (0.004 to 0.28). For the 16 values given the mean is 0.0141 (95% CL=0.0108-0.0174). There is thus a degree of inherent variability in the system. We do not believe Figure 2 . In addition to the lines described in Materials and methods, also included are COR-L51, COR-L88 and H2Fd. The first of these is a small cell line from an untreated patient; the second is a small cell line from a patient with recurrent disease following multi-drug chemotherapy (Baillie-Johnson et al., 1985) and the third is a subline from a small cell line (MAR) which had been treated three times in vitro with ADM to a low level of survival and allowed to regrow. It may be seen that the data for all lines other than H69/LX4 can be covered by a factor of 5 x in ADM sensitivity and that the sensitivity of line H69/LX4 is totally outside this range. carried out as previously described but with the addition of 6.6 pM verapamil to matched dishes. This dose of verapamil has been extensively used by others (Tsuruo et al., 1983a, b) in this type of investigation and we found it to have no growth inhibitory effects on its own. We were in fact able to use doses of verapamil alone as high as 30 4uM without causing significant inhibition of growth in H69/P cells. The results are shown in Table III . It may be seen that in all three experiments, the addition of verapamil led to a large but not total removal of resistance from line H69/LX4 whilst having little or no effect on the sensitivity of H69/P cells. compared the ADM content per cell of H69/P and H69/LX4 cells exposed to ADM for 1 h in order to determine the equilibrium content for short-term exposure. The data from a typical experiment are shown in Figure 3 . The ADM content of resistant subline H69/LX4 was around half of that in parent line H69/P. Similar results were obtained in three replicate experiments although the absolute levels of uptake were different between experiments. We additionally determined the ADM content of H69/P and H69/LX4 cells when exposed to 0.4pgml-1 of ADM for 24 or 48h. (This is the ADM concentration in which subline H69/LX4 is maintained.) In the first experiment incubation was carried out at 1.3 x 106 cells in 5 ml whilst in the second, 1 x 106 cells in 5ml was used. The results are shown in Table IV . It may be seen that H69/P cells had around 6 times the ADM content of H69/LX4 cells at both 24 and 48 h in the first experiment, and that the ratio in the second experiment was very similar.
Effect of verapamil
Properties of resistant lines -MOR and COR-L23 Parent lines of adenocarcinoma MOR and large cell carcinoma COR-L23 were compared with their ADM-resistant variants with regard to ADM sensitivity and ADM content after short-term exposure. The variants used in these studies were MOR (0.2R) and COR-L23 (0.2R) both selected for growth in 0.2 pg ml-' of ADM. Figure 4 shows the data from one cell growth experiment. For MOR and its resistant variant the ratio of ID80 values was 7.7 whereas for COR-L23 and its resistant variant, the ratio was 12.3. In a repeat experiment the ratios were 3.1 and 7.8 respectively. The ADM contents of cells exposed to aThese values are based on the numbers of cells originally inoculated into the dishes. After 24h, the total number of phase-contrast viable cells recovered from both H69/P and H69/LX4 was within 20% of the initial inoculum. By 48 h, however, only 50% of the original cell number could be recovered from dishes of H69/P in which ADM (0.4 Mgml-') was present. No such reduction was seen, however, for H69/LX4. The ratio of cellular content given for 48 h is, therefore, probably an underestimate of the true ratio based on ADM/viable cell at the time of assay. ADM for 1 h are shown in Figure 5 . A repeat experiment (not shown) gave very similar results. It may be seen that both MOR and COR-L23 had clearly reduced content of ADM compared with the respective parent lines.
Discussion
In this paper we have described the isolation and partial characterisation of ADM-resistant variants of three human lung cancer cell lines. A variety of techniques have been used by other workers to produce ADM-resistant sublines of murine cells including growth in low concentrations for many months followed by cloning (Belli & Harris, 1979 ), a double cloning over 6-8 weeks (Hill et al., 1985) or growth of cells in rapidly increasing concentrations of ADM over 6-8 weeks (Giavazzi et al., 1983 The ADM-resistant subline of NCI-H69 was also resistant to colchicine, vincristine and VP16. This is in agreement with the general pattern of 'pleiotropic drug resistance' which has been previously described (Bech-Hansen et al., 1976; Biedler et al., 1983; Giavazzi et al., 1983) .
Cross-resistance of ADM-resistant lines to VP16 and to mitozantrone has also been reported for in vivo systems by Schabel et al. (1983) . Lack of crossresistance to BLM by ADM-resistant lines has also been previously described (Bech-Hansen et al., 1976; Giavazzi et al., 1983) . A lack of cross-resistance to ACL in ADM-resistant L5178 mouse cells has been reported by Hill et al. (1985) and the data of Schabel et al. (1983) are suggestive that ADM resistant cells may be less than fully cross-resistant to ACL. Similarly, data for CCNU are not available but the closely related nitrosourea BCNU was found to be fully active against an ADM-resistant line (Schabel et al., 1983) . The published data for MEL are conflicting. In the study of Elliot and Ling (1981) , their ADM-resistant CHO cell was found to be significantly resistant to MEL, whereas the MEL sensitivity of parent and ADM-resistant lines was similar in the study by Schabel et al. (1983) . Our results indicate that some degree of resistance to MEL occurs in fully resistant NCI-H69 cells. The ADM analogues, 4'EPI and 4'DEOXY have previously been studied by Hill et al. (1985) and whereas the former agent was found to ge fully cross-resistant with ADM, there was no cross-resistance with the latter agent. In our studies reported here, however, cross-resistance was seen with both drugs. In general therefore the crossresistance patterns shown by our ADM-resistant human cells are similar to results previously described by others for rodent cells. The lack of cross-resistance for ACL is of particular interest to us as we and others have recently reported preliminary observations on lack of cross-resistance between ADM and a family of novel anthracyclines recently synthesised by Roche Products Ltd Scott et al., 1985) . Our studies on structure/activity relationship for these compounds and on the mechanism of cytotoxicity are continuing.
Our observations that ADM-resistant human lung cancer cells show a reduced drug content after a given exposure are in accordance with previous observations on rodent cells (Kessel et al., 1968; Dano, 1973) . The reduced ADM content is believed' to be due to an increased efficiency of active drug efflux (Skovsgard, 1978; Inaba et al., 1979) . Use of the calcium transport blocker, verapamil, to block such active efflux has been described by Tsuruo et al. (1982 Tsuruo et al. ( , 1983a . It is interesting that the equilibrium content of ADM in H69/P and H69/LX4 variants of NCI-H69 cells differs by only around a factor of 6 x whereas the ratio of ADM doses to suppress growth lies in the range 40-200 x. Studies of the relationship between cellular ADM accumulation and cytotoxicity are currently in progress and will shed light on the significance of this observation.
A number of studies have indicated that multidrug resistance is frequently associated with gene amplification and changes in cellular protein compostion (Ling, 1982; Beck, 1983 , Biedler et al., 1983 Kartner et al., 1983; Robinson et al., 1984) . Our continuing studies are therefore directed towards identification and characterisation of genetic changes and associated differences in protein composition in normal and drug-resistant human lung cancer cells.
